Advertisement
News
Subscribe to MDT Magazine News

Major Medical Center in India is Country's First to Offer Fast Arc-based Radiation Therapy Technique for Patients With Cancer

October 25, 2010 7:34 am | by Bio-Medicine.Org | Comments

NEW DELHI, Oct. 25 /- In Medanta Cancer Institute's first two Elekta VMAT cases, physicians were able to simultaneously exploit both the precision and speed benefits of this novel technique. Both patients had cranial tumors located near critical structures—requiring precise...

TOPICS:

Frost & Sullivan Recognizes Visage Imaging, Inc. for its Medical Imaging Informatics in Healthcare Innovation

October 25, 2010 7:32 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Oct. 25 /- Based on its recent analysis of the medical imaging informatics market, Frost & Sullivan recognizes Visage Imaging, Inc. with the 2010 North American Frost & Sullivan Healthcare Innovation of the Year Award. (Logo:  ...

TOPICS:

TDI introduces new 4.1kW, 28V liquid cooled DC-DC converter

October 25, 2010 6:36 am | by I-Micronews | Comments

TDI has developed LiquaCore? (patent pending) power management technology which employs liquid cooling from a modular and scalable architecture.

Advertisement

IR expands family of automotive directFET2 power MOSFETs with system scalability

October 25, 2010 6:36 am | by I-Micronews | Comments

International Rectifier, IR® announced the expansion of its family of automotive DirectFET®2 power MOSFETs that deliver exceptional power density, dual-sided cooling and minimal parasitic inductance and resistance for heavy load applications, including Electric Power Steering (EPS), power...

Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer

October 25, 2010 6:35 am | by Bio-Medicine.Org | Comments

EAST NORRITON, Pa., Oct. 25 /- Tengion, Inc. (Nasdaq: TNGN ), a leader in regenerative medicine, announced today that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit ™ in the first patient as part of the ongoing clinical trial evaluating the Company's...

TOPICS:

GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch'

October 25, 2010 6:33 am | by Bio-Medicine.Org | Comments

LILLE, France and CAMBRIDGE, Mass., Oct. 25 /- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today...

TOPICS:

CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe

October 25, 2010 6:33 am | by Bio-Medicine.Org | Comments

ATLANTA, Oct. 25 /-  CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has begun European distribution of PerClot®, a novel polysaccharide hemostatic agent used to control bleeding during...

TOPICS:

Panasonic Makes Investment in Houston-based CardioNexus Corp.

October 25, 2010 6:33 am | by Bio-Medicine.Org | Comments

SECAUCUS, N.J., Oct. 25 /- Panasonic Corporation of North America has completed an investment in CardioNexus Corporation, a portfolio company of Houston's Fairway Medical Technologies which works closely with the Texas Medical Center. The move is part of Panasonic's plans to establish...

TOPICS:
Advertisement

Emeritus buys Weston for $18 million

October 25, 2010 5:45 am | by The Associated Press | Comments

Emeritus Corp., a provider of senior living services, said Monday it will buy The Weston Group Inc., one of its suppliers, for $18 million.The Weston Group, of Easton, Pa., provides rehabilitation services and medical equipment to the senior living industry. Weston's annual revenue is about $37...

Psychiatric Solutions facility subpoenaed by DOJ

October 25, 2010 5:45 am | by The Associated Press | Comments

Psychiatric Solutions Inc. said one of its inpatient facilities in Philadelphia received a subpoena from the Department of Justice, according to a Securities and Exchange Commission filing on Monday.In the filing, the company said it received the subpoena on Oct. 20. It did not disclose details...

PAREXEL International to Present at Oppenheimer Healthcare Conference and Morningstar Annual Stocks Forum

October 25, 2010 4:35 am | by Bio-Medicine.Org | Comments

BOSTON, Oct. 25 /- PAREXEL International Corporation (Nasdaq: PRXL ) announced today it will be presenting at the Oppenheimer Healthcare Conference in New York.  James Winschel, Senior Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 2:45 p.m....

TOPICS:

PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santoprene™ TPV Medical Grades

October 25, 2010 4:35 am | by Bio-Medicine.Org | Comments

CLEVELAND, Oct. 25 /- PolyOne Corporation announced that PolyOne GLS Thermoplastic Elastomers has been chosen by ExxonMobil Chemical Company to be its primary marketing specialist for thermoplastic vulcanizate (TPV) medical products made using ExxonMobil Chemical's Santoprene™ TPV....

TOPICS:

Roper Industries Announces Record Third Quarter Results

October 25, 2010 4:35 am | by Bio-Medicine.Org | Comments

SARASOTA, Fla., Oct. 25 /- Roper Industries, Inc. (NYSE: ROP ) reported record results for its third quarter ended September 30, 2010.   Net earnings for the third quarter were $84 million, a 49% increase over the third quarter of 2009, and diluted earnings per share (DEPS) were...

TOPICS:

Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase

October 25, 2010 4:32 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., Oct. 25 /- Adeona Pharmaceuticals, Inc., (Amex: AEN ) announced today that its Chief Executive Officer, James S. Kuo, M.D., M.B.A., will provide the keynote address at the Emerging Biosciences Showcase during the 2010 MichBio Expo & Conference. The 2010 MichBio Expo...

TOPICS:

Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections

October 25, 2010 12:33 am | by Bio-Medicine.Org | Comments

VIENNA, Oct. 25 /- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa , a leading cause of hospital-acquired infections...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading